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Abstract. Background and objective. Despite animal studies have shown a generalisation of the 
bupropion cue to cocaine, this drug has been used in cocaine abuse with mixed results. We here 
aimed at describing two cases which contradict current knowledge. Case Reports. We describe two 
cases of former cocaine abusers who reported a cocaine-like sensation upon taking bupropion. 
Bupropion improved patients’ depression without any increase in cocaine craving. One of the 
patients increased without doctor consultation his dose on an as needed basis. Conclusions. The 
issue of bupropion cue generalisation to cocaine needs further elucidation. People with past cocaine 
addiction need to be informed on the potential of bupropion to elicit cocaine-like cues and be 
invited to adhere to medical prescription, because bupropion has been associated with fatalities in 
some cases. 
Il bupropione percepito come uno psicostimolante da due pazienti con anamnesi pregressa di 
abuso di cocaina. Riassunto. Contesto e obiettivo. Sebbene studi su animali abbiano dimostrato 
una generalizzazione del cue del bupropione alla cocaina, tale farmaco è stato utilizzato nell’abuso 
di cocaina con risultati misti. Il nostro obiettivo è stato di descrivere due casi che contraddicono le 
conoscenze attuali. Casi clinici. Riportiamo due casi di pazienti che hanno riferito una sensazione 
cocaino simile in due ex-utilizzatori di cocaina. Il bupropione ha migliorato la depressione di questi 
pazienti senza aumentare il craving cocainico. Uno di questi pazienti ha aumentato la dose, pro re 
nata, senza consultarsi col medico. Conclusioni. La questione della  generalizzazione del cue del 
bupropione alla cocaina va ulteriormente delucidata. Gli ex-cocainomani vanno informati sulla 
possibile associazione del bupropione con cue cocaino simili e invitati ad aderire alle prescrizioni 
mediche, perché l’assunzione di bupropione è stata associata in qualche caso con fatalità. 
Key words: Bupropion; cocaine abuse; depression; internal stimulant cue; monoamine transporter inhibitors 
Parole chiave: Bupropione; abuso di cocaina; depressione; cue interno da psicostimolanti; inibitori dei trasportatori 
delle mono ammine  
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Increased synaptic dopamine levels in the dorsal striatum appear to mediate cocaine craving in 
cocaine-experienced individuals [1]. Cocaine craving predicts relapse to subsequent cocaine use [2]. 
The dopamine transporter inhibitor, amineptine, which has been used for some time as an 
antidepressant, and which has been withdrawn due to its abuse/dependence potential, was shown to 
generalise its cue to other weakly dopaminergic antidepressants, like fluoxetine [3] and venlafaxine 
[4], hence inducing cross-abuse/dependence. The dopamine/noradrenaline-reuptake inhibitor 
bupropion has long been used in the US as an antidepressant, before receiving approval for nicotine 
dependence. Due to its mechanism, it could be expected to mimic other dopamine transporter 
inhibitors and generalise its cue to them. In fact, it is long known that bupropion produces cocaine-
appropriate responses in the self-administration, lever pressing paradigm in several animals, 
including the pigeon [5], the rat [6,7], and baboon and rhesus monkeys [7,8], substituting 
completely for cocaine at the higher doses, although there has recently been a negative report in the 
rat, in which only amphetamine and nicotine were found to substitute for the bupropion cue [9]. 
Bupropion has been used for cocaine addiction in individuals on methadone maintenance 
programmes [10,11] with some success, but despite reducing reported cocaine use, open [12] and 
controlled studies showed that bupropion did not significantly affect cocaine-related behaviour [13], 
partly cooling the enthusiasm about its usefulness in cocaine addiction. However, this occurred at 
therapeutic doses, not exceeding 300 mg/day. In a non-therapeutic human experiment, cocaine users 
provided higher ratings for the positive subjective effects of cocaine while taking 100 or 200 mg 
bupropion than when they were not taking bupropion, reducing simultaneously their cocaine 
preference with respect to placebo [14]. Combined, these findings do not yield a definitive response 
as to whether bupropion affects cocaine cues in the human. We report two cases showing that in 
fact, in line with previous animal literature, bupropion elicits a cocaine-like cue without increasing 
craving for cocaine. 
 
Case Reports 
Case1. A 28-year-old man with past history of drug misuse (including cocaine, alcohol, 
tetrahydrocannabinol, and lysergic acid diethylamide, but not amphetamine (or its derivatives) 
developed chronic depression with anhedonia, interrupted by brief periods of euphoria. The patient 
was a socially withdrawn university student with poor academic performance, the reason for which 
he sought psychotherapy. His psychotherapist referred him to us for pharmacotherapy, considering 
psychotherapy alone to be insufficient to treat his patient’s condition. 
When he came to our attention he was 26. The patient was considerably anergic, with motor 
retardation, decreased expressiveness, poverty of speech,  reduced ideation, blunted affect, anxiety, 
difficulties with concentration, intrusive thoughts, and somaesthetic disturbances. His depression 
had developed subtly from the age of 19, reaching a peak when he was 25. About that time he had 
started his polydrug misuse, including cocaine, until he reached the age of 23. He was poorly 
motivated, anhedonic, with suicidal ideation, and suffering from sleep disturbances, scoring 30 on 
the Hamilton Rating Scale for Depression  (Ham-D) [15]. We diagnosed him with DSM-IV-TR 
bipolar disorder, type II, moderate depressive episode, based on a SCID-I interview, comorbid with 
borderline personality disorder, based on a SCID-II interview. 
Treatment with both oral, slow-release bupropion, 150 mg/day, and immediate-release quetiapine, 
25 mg at bedtime, was started. At the two-week follow-up, he reported thought acceleration and 
restlessness when going to bed, which he described as similar to those post-cocaine binges he had 
experienced in the past. This was paralleled by an increase in self-esteem and increased self-
confidence, as when he was abusing cocaine. He characteristically stated “This treatment reminds 
me of when I was taking cocaine”. This sensation lasted for about two weeks, and by the third week 
these sensations disappeared. At the same time, his depressive and sleep symptoms had improved 
considerably, with his Ham-D scores dropping to 24, and then to 20 after three months of treatment,  
progressively reaching a score of  16 one year later (cut-off, 7). 
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Case2. A 56-year-old man reached our attention after a serious suicide attempt. He owned a 
successful bookshop, but faced economic difficulties due to his pathological gambling and cocaine 
addiction. He started developing cocaine abuse at the age of 52, increasing it with time to about 1 g 
on three occasions per week in a short time, thereafter maintaining this weekly dose. His mood 
rapidly deteriorated following his father’s death four years ago, and then gradually worsened  over 
time. Following a serious suicide attempt, he was referred to our unit. On admittance, he had scored 
26 on the Ham-D scale and was started on 150 mg/day slow-release bupropion, 1000 mg/day 
controlled-release valproate, 10 mg oral olanzapine at bedtime, and diazepam p.r.n.. Based on 
SCID-I and -II interviews we made diagnosis of bipolar disorder, type I, comorbid with 
pathological gambling and cocaine use disorder; we diagnosed comorbid gambling because it 
occurred also independently from manic episodes. One month later he had already stopped both 
cocaine misuse and  gambling activities; this was paralleled by mood improvement. Bupropion 
dosage was then increased to 150 mg b.i.d. Two months later he had reached a score of 16 on the 
Ham-D. However, marital conflicts did not improve. In coincidence with intense conflicts, his 
depression worsened, prompting him to increase bupropion intake to 150 mg t.i.d. and olanzapine to 
10 mg b.i.d. In particular, bupropion reportedly made him feeling overstimulated and active, as 
when he was taking cocaine. Although his family and economic problems persisted eight months 
later, his Ham-D scores had dropped to 10, which is mild depression. 
Both patients gave free, informed consent for all treatment received as well as for the publication of 
their cases. 
 
Discussion. In line with the existence of overlap between the mechanisms of bupropion and cocaine 
[5-8], our two cases seem to suggest  that bupropion intake elicits cocaine-like cues in cocaine-
experienced humans. Bupropion acts by inhibiting dopamine and noradrenaline transporters, hence 
increasing the intra-synaptic concentrations of these neurotransmitters [16]. Cocaine blocks both 
these transporters and the serotonin transporter as well [17], while amphetamine is a dopamine 
releaser and dopamine transporter blocker [18,19]. Hence, the theoretical basis for cross-elicitation 
of their cues is sufficient to let us hypothesise that our cocaine-exposed patients were able to 
identify a cocaine-like cue with bupropion intake. Hence, cocaine-exposed subjects are able to 
identify bupropion intake as having a cue similar to cocaine. This is further backed by animal 
studies showing generalisation of the bupropion cue to amphetamine, cocaine, and caffeine [5-8,20] 
and substitution of both bupropion and cocaine for methamphetamine [21]. However, it is in 
contrast with the results of another study, which found nicotine and methamphetamine, but not 
cocaine substitution for bupropion in the rat [9]. 
Differently from previous reports [22,23] we observed no psychotic symptoms in these two 
patients. Both our patients were on antipsychotic medication, and this might have prevented 
psychotic symptoms. It should be stressed that antipsychotic drugs behave differently from one 
another as regards co-administered bupropion, at least in facilitating smoking cessation, but the two 
atypical antipsychotics used in our patients did not interact with bupropion at this respect [24]. 
Our second patient used bupropion not according to prescription; clinicians must inform their 
patients about possible dangers arising from such practice, since five fatalities with bupropion 
intake have been recorded by the National Programme on Substance Abuse Deaths in the UK 
(Corkery, personal communication). 
 
Conclusions. Despite the neurochemical background of addictions and the mechanism of action of 
bupropion, we did not observe negative effects of bupropion on cocaine craving in former cocaine 
users, even in the case of inappropriate dose self-adjustment. However, a generalisation of the 
bupropion cue to cocaine, which has not been previously reported in medical literature, was found 
in two patients, leading us to question the universal validity of animal studies showing bupropion to 
generalise to amphetamine, but not cocaine. Clinicians should be aware of the possibility that 
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bupropion may elicit cocaine-like cues in cocaine-experienced individuals and ask about it to their 
patients, cautioning them for the dangers of non-prescription use of bupropion. 
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